Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,790 Shares

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,790 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the sale, the chief executive officer now directly owns 643,299 shares of the company’s stock, valued at approximately $7,385,072.52. The trade was a 0.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Oleg Movchan also recently made the following trade(s):

• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23.

Enfusion Trading Up 0.4 %

Shares of NYSE:ENFN opened at $11.45 on Thursday. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 286.20, a PEG ratio of 1.85 and a beta of 0.96. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The firm’s 50-day moving average is $10.95 and its 200 day moving average is $9.85.

Enfusion (NYSE:ENFN) last issued its earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, equities analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus boosted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.13.

Institutional Investors Weigh In On Enfusion

A number of hedge funds and other institutional investors have recently bought and sold shares of ENFN. Harbor Capital Advisors Inc. lifted its position in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the last quarter. Belvedere Trading LLC purchased a new position in shares of Enfusion in the third quarter worth $114,000. Impax Asset Management Group plc raised its holdings in shares of Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after buying an additional 136,948 shares during the last quarter. Versor Investments LP purchased a new position in shares of Enfusion in the third quarter worth $501,000. Finally, Royce & Associates LP raised its holdings in shares of Enfusion by 35.4% in the third quarter. Royce & Associates LP now owns 99,715 shares of the company’s stock worth $946,000 after buying an additional 26,045 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.